B Group Inc. Takes $24.16 Million Position in Insmed Incorporated (NASDAQ:INSM)

B Group Inc. purchased a new stake in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 350,000 shares of the biopharmaceutical company's stock, valued at approximately $24,164,000. Insmed comprises 14.8% of B Group Inc.'s portfolio, making the stock its 3rd largest position. B Group Inc. owned approximately 0.20% of Insmed as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in INSM. Vanguard Group Inc. increased its stake in Insmed by 6.3% during the fourth quarter. Vanguard Group Inc. now owns 18,218,973 shares of the biopharmaceutical company's stock worth $1,257,838,000 after purchasing an additional 1,075,796 shares during the period. Capital International Investors increased its stake in Insmed by 9.1% during the 4th quarter. Capital International Investors now owns 7,116,997 shares of the biopharmaceutical company's stock worth $491,357,000 after buying an additional 593,206 shares during the period. Geode Capital Management LLC lifted its holdings in Insmed by 7.2% during the 4th quarter. Geode Capital Management LLC now owns 4,087,143 shares of the biopharmaceutical company's stock worth $282,243,000 after buying an additional 273,759 shares in the last quarter. Artisan Partners Limited Partnership boosted its position in Insmed by 8.4% in the 4th quarter. Artisan Partners Limited Partnership now owns 3,126,339 shares of the biopharmaceutical company's stock valued at $215,842,000 after buying an additional 242,242 shares during the period. Finally, FIL Ltd grew its stake in shares of Insmed by 8.1% in the fourth quarter. FIL Ltd now owns 2,638,160 shares of the biopharmaceutical company's stock worth $182,139,000 after acquiring an additional 198,412 shares in the last quarter.

Insmed Stock Performance

NASDAQ:INSM traded up $0.73 during trading hours on Friday, reaching $69.69. 13,610,728 shares of the company's stock were exchanged, compared to its average volume of 2,302,671. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The firm has a market capitalization of $12.67 billion, a price-to-earnings ratio of -12.47 and a beta of 1.07. Insmed Incorporated has a 1-year low of $21.92 and a 1-year high of $84.91. The company has a 50-day moving average of $74.38 and a 200 day moving average of $73.53.

Insmed (NASDAQ:INSM - Get Free Report) last posted its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.15). The company had revenue of $104.44 million for the quarter, compared to analyst estimates of $102.31 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. Research analysts anticipate that Insmed Incorporated will post -4.56 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. JPMorgan Chase & Co. lifted their target price on Insmed from $83.00 to $92.00 and gave the company an "overweight" rating in a report on Friday, February 7th. Truist Financial lifted their price objective on Insmed from $105.00 to $108.00 and gave the company a "buy" rating in a research note on Friday, February 21st. UBS Group upped their target price on shares of Insmed from $105.00 to $110.00 and gave the stock a "buy" rating in a research note on Thursday, March 6th. Guggenheim reiterated a "buy" rating and issued a $101.00 price target on shares of Insmed in a research note on Tuesday, February 25th. Finally, Morgan Stanley increased their price objective on shares of Insmed from $85.00 to $90.00 and gave the company an "overweight" rating in a research report on Thursday, February 6th. One analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $94.00.

Insider Activity at Insmed

In related news, insider Martina M.D. Flammer sold 33,055 shares of the company's stock in a transaction on Thursday, February 6th. The stock was sold at an average price of $80.90, for a total transaction of $2,674,149.50. Following the transaction, the insider now owns 138,053 shares of the company's stock, valued at $11,168,487.70. This represents a 19.32 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Orlov S. Nicole Schaeffer sold 91,140 shares of the firm's stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $80.00, for a total value of $7,291,200.00. Following the completion of the sale, the insider now directly owns 97,083 shares of the company's stock, valued at approximately $7,766,640. This trade represents a 48.42 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 471,797 shares of company stock worth $37,621,239 in the last three months. Insiders own 3.00% of the company's stock.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.